Drug Price Trends for GRISEOFULVIN MICRO

Average Pharmacy Cost for GRISEOFULVIN MICRO

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
GRISEOFULVIN MICRO 500 MG TAB	42794-0012-08	6.48390	EACH	2024-12-18
GRISEOFULVIN MICRO 500 MG TAB	62135-0496-01	6.48390	EACH	2024-12-18
GRISEOFULVIN MICRO 500 MG TAB	23155-0865-01	6.48390	EACH	2024-12-18
GRISEOFULVIN MICRO 500 MG TAB	62135-0496-30	6.48390	EACH	2024-12-18

Griseofulvin Market Analysis and Price Projections

Introduction to Griseofulvin

Griseofulvin is an antifungal medication used primarily to treat dermatophyte infections such as tinea capitis, tinea corporis, tinea cruris, and onychomycosis. It functions by accumulating in keratin-producing tissues and disrupting the fungal cell cycle, thereby inhibiting fungal growth[4].

Market Growth Drivers

The griseofulvin market is anticipated to experience significant growth driven by several key factors:

• Increase in Fungal Infections: The rise in cases of dermatophytosis, particularly post-COVID-19 treatment, is a major driver. Patients who have recovered from COVID-19 often have weakened immunity, making them more susceptible to fungal infections[1].
• Aging Population: The globally rising geriatric population contributes to a higher prevalence of dermatophytosis, as the immune system weakens with age[1].
• Lifestyle Factors: An increase in sedentary lifestyles and the incidence of hospital-acquired diseases also contribute to the higher rate of dermatophytosis[1].

Market Trends

• Post-COVID-19 Impact: The COVID-19 pandemic has accelerated the growth of the griseofulvin market due to the increased incidence of fungal infections among patients with compromised immune systems[1].
• R&D Investments: Potential activities of griseofulvin can be enhanced through investments in the R&D sector, which could lead to new applications and improved formulations[1].
• Regional Growth: The market is segmented into regions such as North America, Europe, Asia Pacific, Middle East & Africa, and Latin America, with each region showing varying growth rates and market shares[3].

Market Size and Forecast

The global griseofulvin market is expected to grow significantly from 2024 to 2031. Here are some key projections:

• Current Market Size: As of 2023, the global griseofulvin market size was estimated to be substantial, with a compound annual growth rate (CAGR) projected to be significant over the forecast period[3].
• Forecast Period: The market size is estimated to grow from 2025 to 2031, driven by increasing demand and new market opportunities[3].

Price Projections and Cost Analysis

The cost of griseofulvin varies based on the formulation and dosage:

• Oral Tablets:
  • Ultramicrocrystalline 125 mg tablets: Approximately $84.77 for a supply of 30 tablets, with a per-unit cost of around $2.83[2].
  • Ultramicrocrystalline 250 mg tablets: Approximately $103.60 for a supply of 30 tablets, with a per-unit cost of around $3.45[2].
  • Microcrystalline 500 mg tablets: Approximately $99.27 for a supply of 30 tablets, with a per-unit cost of around $3.31[2].
• Oral Suspension:
  • Microcrystalline 125 mg/5 mL: Approximately $33.29 for 118 milliliters, with a per-unit cost of around $0.28 per milliliter[2].

Challenges and Restraints

Despite the growth potential, the griseofulvin market faces several challenges:

• Lack of Awareness: Limited awareness about dermatophytosis and its treatment options hampers market growth[1].
• Patient Reluctance: Reluctance among patients to seek treatment for fungal infections also restricts market expansion[1].
• Competitive Landscape: Griseofulvin faces competition from newer antifungal drugs like terbinafine and itraconazole, which have broader spectrums of activity and higher efficacy[1].

Competitive Analysis

The griseofulvin market is competitive, with several key players:

• Major Players: Companies such as GlaxoSmithKline, Dr. Reddy’s Laboratories, Pfizer, and Sun Pharmaceuticals are prominent in the market[1][3].
• Market Strategies: These companies are focusing on strengthening their product portfolios and expanding their business through strategic investments and R&D activities[3].

Regional Analysis

The market is segmented into five major regions:

• North America: This region is expected to contribute significantly to the market growth due to high awareness and advanced healthcare infrastructure.
• Europe: Europe also shows promising growth, driven by an aging population and increased incidence of fungal infections.
• Asia Pacific: This region is expected to grow rapidly due to a large population and increasing healthcare expenditure.
• Middle East & Africa and Latin America: These regions are also expected to contribute to the market growth, albeit at a slower pace compared to other regions[3].

Key Benefits of Market Reports

Market reports on griseofulvin provide several key benefits:

• Analytical Depiction: These reports offer a detailed analysis of the current trends and future estimations to identify imminent investment pockets[1].
• Driver and Restraint Analysis: Reports highlight key drivers, restraints, and opportunities in the market, providing a comprehensive understanding of market dynamics[1].
• Competitive Intensity: Analysis of competitive intensity and future competition shape helps stakeholders make informed decisions[1].

Key Takeaways

• The griseofulvin market is expected to grow significantly due to the rise in fungal infections post-COVID-19.
• The market is driven by factors such as an aging population, sedentary lifestyles, and hospital-acquired diseases.
• Despite challenges like lack of awareness and patient reluctance, the market shows promising growth potential.
• Key players are focusing on R&D and strategic expansions to strengthen their market positions.

FAQs

1. What are the primary uses of griseofulvin? Griseofulvin is primarily used to treat dermatophyte infections such as tinea capitis, tinea corporis, tinea cruris, and onychomycosis[4].

2. How does griseofulvin work? Griseofulvin accumulates in keratin-producing tissues and disrupts the fungal cell cycle by binding to tubulins and microtubule-associated proteins, thereby inhibiting mitosis[4].

3. What are the key drivers of the griseofulvin market? Key drivers include the increase in fungal infections post-COVID-19, a rising geriatric population, and lifestyle factors such as sedentary lifestyles and hospital-acquired diseases[1].

4. What are the challenges faced by the griseofulvin market? Challenges include lack of awareness about dermatophytosis, patient reluctance to seek treatment, and competition from newer antifungal drugs[1].

5. Who are the major players in the griseofulvin market? Major players include GlaxoSmithKline, Dr. Reddy’s Laboratories, Pfizer, and Sun Pharmaceuticals[1][3].

Cited Sources

1. Allied Market Research - Griseofulvin Market Size & Growth | Analysis & Forecast 2030
2. Drugs.com - Griseofulvin Prices, Coupons, Copay Cards & Patient Assistance
3. Cognitive Market Research - Global Griseofulvin Market Report 2024 Edition
4. International Journal of Pediatric Dermatology - Griseofulvin in Children: Revisiting the Vintage Drug
5. Drug Central - Griseofulvin Drug Card